Immix Biopharma Announces Share Repurchase Program
Immix Biopharma Announces Share Repurchase Program Immix Biopharma, Inc. (NASDAQ:IMMX) LOS ANGELES, May 09, 2022…
News
Alimera Sciences Reports First Quarter 2022 Results
Consolidated Net Revenue of $11.9 Million Up 6% vs. First Quarter of 2021 U.S. Net…
Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
Company enters into collaborations with leading next generation sequencing (NGS) companies to facilitate trial enrollment…
Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results
ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a…
Apexigen to Host Investor Day on Antibody Therapeutic Pipeline and Unique APXiMAB™ Platform
-Webinar to be held Monday, May 16th at 8:00 a.m. PT/ 11:00 a.m. ET- SAN…
Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy
Initial data from open label Phase 2a study expected in late 2022 IRVINE, Calif., May…
LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers
Mavacamten demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers Study was…
Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer
Dr. Sandborn brings a wealth of clinical experience and knowledge to Ventyx as we advance our…
Arch Therapeutics’ Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring
World-renowned Wound Care Leaders, Terry Treadwell, MD, FACS and Brock Liden, DPM, Shared Insights on…
Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates
DALLAS, May 09, 2022 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering…
Adaptimmune Reports First Quarter Financial Results and Business Update
– Pooled data from Cohort 1 of the SPEARHEAD-1 trial and the Phase 1 trial…
Genenta Appoints Industry Veteran Tim Obara as Head of Business Development
Extensive experience in business development with AstraZeneca and GSK MILAN, Italy and NEW YORK, May…
Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results
Upcoming PDUFA date of May 24, 2022 for VP-102 NDA for the treatment of molluscum…
VectivBio to Participate at the Bank of America 2022 Healthcare Conference
BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) — VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a…
Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study
CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”, or “the Company”) (TSX:RVX),…
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022
– Cash runway extended into 2024 – – Strengthened financial position with achievement of $30…
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b…
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results
FDA review of NDA for FT218 continues; launch readiness preparations on-track to support potential commercial…
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
– Initial data from Phase 1b trial of FTX-6058 in sickle cell disease to be…
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting
–Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral…